Indeed, SEMA3A-mutant mice or the pharmacological-based inhibition of SEMA3A protected from these kidney diseases, suggesting the potential of SEMA3A inhibitory treatment in clinic use in the future. This evidence concerns the gene SEMA3A and kidney disorder.